Clinical Trial

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify changes in Carbonic Anhydrase IX (CAIX) expression induced by hypoxia-inducible factor 2 alpha (HIF-2α) inhibition by initiating belzutifan single agent therapy and imaging CAIX expression with 89Zr-DFO-girentuximab PET before and 4 weeks after initiating treatment. This will be the first study to evaluate potential changes in CAIX expression altered by belzutifan. Information gained from this study will be leveraged to develop combinations of belzutifan with CAIX targeted agents including radioimmunotherapy in the future.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-09-01 -> 2028-09-01 2026-07-31
minor Completion pushed: 2027-10-01 -> 2028-10-01 2026-07-31
Trial Details
NCT Number NCT07179770
Lead Sponsor NYU Langone Health
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Clear Cell Renal Cell Carcinoma
Enrollment 12 participants
Start Date 2025-09-15
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30